<DOC>
	<DOCNO>NCT02603809</DOCNO>
	<brief_summary>The main objective study explore effect ERA - different dose strength - efficacy , safety tolerability subject essential hypertension</brief_summary>
	<brief_title>Clinical Study Explore Effects Actelion 's Latest Endothelin Receptor Antagonist ( ERA ) - Different Dose Strengths - Efficacy , Safety Tolerability Subjects With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure Mildtomoderate essential hypertension without ongoing antihypertensive treatment ( ) No contraindication stop ( accord label ) antihypertensive treatment ( ) Women childbearing potential must negative pregnancy test use reliable method contraception Severe hypertension ( grade 3 ) : mean sit systolic/diastolic BP ( SiSBP/SiDBP ; measure OBPM ) â‰¥ 180/110 mmHg , respectively . Secondary hypertension Known hypertensive retinopathy great KeithWagener Grade 2 Myocardial infarction , percutaneous transluminal coronary angioplasty , coronary artery bypass graft within 12 month prior randomization Unstable angina within 6 month prior randomization Heart failure New York Heart Association class III IV Valvular defect ( severe aortic mitral valve disease ) and/or hemodynamically relevant rhythm disturbance Clinical evidence cerebrovascular insufficiency cerebrovascular accident within 6 month prior randomization . Subjects work night shift Body mass index &lt; 20 kg/m2 &gt; 40 kg/m2 Treatment medication may affect BP ( e.g. , treatment psychiatric disease , ophthalmic preparation ) Treatment strong cytochrome P450 3A4 ( CYP3A4 ) isoenzyme inhibitor inducer Treatment guanethidine and/or mineralocorticoid receptor antagonist within 1 month prior Screening ( Visit 1 ) Treatment another investigational treatment within 1 month prior Screening ( Visit 1 ) Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>